Ipratropium bromide 0.5 mg/3 mL (0.017%), albuterol (as sulfate) 2.5 mg/3 mL (0.083%); soln for inh. Not for primary treatment of acute attack. Avoid excessive use. Discontinue if paradoxical ...
Active ingredients of dual-action Combivent® (ipratropium bromide and albuterol sulfate) Inhalation Aerosol now delivered by new propellant-free inhaler RIDGEFIELD, Conn., Oct. 10, 2011 /PRNewswire/ - ...
Although ipratropium inhalation aerosol is minimally absorbed into bromide doses of mcg given via a metered-dose with a spacer device may be used as. Orally inhaled ipratropium is not indicated as a ...
Stay ahead of policy, cost, and value—subscribe to AJMC for expert insights at the intersection of clinical care and health economics.
RIDGEFIELD, Conn., April 13 /PRNewswire/ -- Boehringer Ingelheim Pharmaceuticals, Inc. (BIPI) today announced that the U.S. Food and Drug Administration (FDA) has determined that the "essential use" ...
San Diego, Calif., May 19, 2009 – Data from two presentations highlighting the use of Perforomist® (formoterol fumarate) Inhalation Solution in moderate to severe chronic obstructive pulmonary disease ...
To earn CME related to this news article, click here. March 4, 2009 — The US Food and Drug Administration (FDA) has approved safety labeling revisions to provide additional counseling information for ...
Napa, Calif., (May 14, 2009) – Dey, L.P., a subsidiary of Mylan Inc. (NYSE: MYL), announced today that data from two presentations highlighting the use of Perforomist® (formoterol fumarate) Inhalation ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback